New scan could reveal hidden pancreatic cancer

NCT ID NCT07342231

Recruiting now Diagnosis Sponsor: Tata Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new type of PET scan that uses a special tracer to light up a protein called FAP, found on pancreatic tumor tissue. The goal is to see if this scan can detect cancer spread that standard CT scans miss. Researchers will compare the new scan with CT in 60 adults with pancreatic cancer to see if it improves accuracy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gallium-68 labeled FAP inhibitor (FAPi) for PET imaging
What this could lead to: If successful, this scan could help doctors see hidden cancer spread in pancreatic cancer patients, leading to more accurate staging and better treatment choices.
What could go wrong: This is a small, early exploratory study with only 60 participants. The new scan may not prove more useful than standard CT, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA PANCREAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA PANCREAS PANCREATIC CANCER

Contacts and locations

Locations

Tata Memorial Hospital, Mumbai, India
RECRUITING

Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.